Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1029-1034

  Jung, Phill Seung ^a   Kim, Dae Yeon ^a   Kim, Moon Bo ^b   Lee, Shin Wha ^a   Kim, Jong Hyeok ^a   Kim, Yong Man ^a   Kim, Young Tak ^a   Hoffman, Robert M ^c,d   Nam, Joo Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Metabio Institute   (South Korea)

^c ANTICANCER INC   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Carboplatin; Chemosensitivity; Correlation; Epithelial ovarian cancer; HDRA; Histoculture drug response assay; Individualized therapy; Prediction; Prospective clinical trial; Taxol

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; TOPOTECAN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HISTOCULTURE DRUG RESPONSE ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENCE RISK; SOUTH KOREA; TISSUE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; TUMOR CELLS, CULTURED;

EID: 84875900369     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Joo WD, Lee JY, Kim JH, Yoo HJ, Roh HJ, Park JY, Kim DY, Kim YM, Kim YT and Nam JH: Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol 20: 96-100, 2009.
3. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR and Hoffman RM: Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20: 2049-2054, 2000.
4. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y and Nozawa S: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15: 445-452, 2005.
5. Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH and Kim YT: In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer. Acta Med Okayama 66: 271-277, 2012.
6. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH and Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1987.
7. Leighton J: A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. J Natl Cancer Inst 12: 545-561, 1951.
8. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 5: 133-143, 1991.
9. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M et al: High in vitro-in vivo correlation of drug response using spongegel- supported three-dimensional histoculture and the MTT end point. Int J Cancer 51: 489-498, 1992.
10. Furukawa T, Kubota T, Watanabe M, Kase S, Takahara T, Yamaguchi H, Takeuchi T, Teramoto T, Ishibiki K, Kitajima M et al: Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point. Anticancer Res 12: 1377-1382, 1992.
11. Hoffman RM: To do tissue culture in two or three dimensions? That is the question. Stem Cells 11: 105-111, 1993.
12. Hoffman RM: In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 15: 99-111, 1993.
13. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H et al: Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1: 1537-1543, 1995.
14. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305-311, 1995.
15. Hoffman RM. Histocultures and their use. In: Encyclopedia of Life Sciences. John Wiley and Sons, Ltd.: Chichester, 2010, published online. DOI: 10.1002/9780470015902.a0002573.pub2.
16. Nakamura J, Imai E, Yoshihama M, Sasano H and Kubota T: Histoculture drug response assay, a possible examination system for predicting the antitumor effect of aromatase inhibitors in patients with breast cancer. Anticancer Res 18: 125-128, 1998.
17. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS and Lee JS: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24: 209-218, 2009.
18. Yoon YS, Kim CW, Roh SA, Cho DH, Kim GP, Hong YS, Kim TW, Kim MB and Kim JC: Applicability of histoculture drug response assays in colorectal cancer chemotherapy. Anticancer Res 32: 3581-3586, 2012.
19. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Hoffman RM, and Shah J: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head and Neck 24: 437-442, 2002.
20. Hoffman RM: Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3: 86-92, 1991.
21. Yoshimasu T, Oura S, Maebeya S, Tanino H, Bessho T, Arimoto J, Sakurai T, Matsuyama K, Naito Y, Furukawa T, Yano T, Suzuma T and Hirai I: Histoculture drug response assay on nonsmall cell lung cancer. Gan To Kagaku Ryoho 27: 717-722, 2000.
22. Tamaki T, Oura S, Yoshimasu T, Ota F, Nakamura R, Shimizu Y, Kiyoi M, Naito K, Hirai Y and Okamura Y: Histoculture drug response assay guided concurrent chemoradiotherapy for nonsmall cell lung cancer. Kyobu Geka 61: 31-35, 2008.
23. Tanahashi M, Yamada T, Moriyama S, Suzuki E and Niwa H: The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer. Kyobu Geka 61: 26-30, 2008.
24. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, Arimoto J, Yoshimasu T, Hirai I, Bessho T, Suzuma T, Sakurai T and Naito Y: Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 21: 4083-4086, 2001.